Literature DB >> 33776917

The Centrality of Obesity in the Course of Severe COVID-19.

Danfei Liu1, Tongyue Zhang1, Yijun Wang1, Limin Xia1.   

Abstract

The ongoing coronavirus disease 2019 (COVID-19) pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global public health challenge. Most patients do not experience severe complications, but approximately 25% of patients progress to acute respiratory distress syndrome (ARDS), and the mortality rate is approximately 5-7%. Clinical findings have determined several risk factors for severe complications and mortality in COVID-19 patients, such as advanced age, smoking, obesity, and chronic diseases. Obesity is a common and serious health problem worldwide that initiates a cascade of disorders, including hypertension, cardiovascular disease (CVD), diabetes mellitus, and chronic kidney disease (CKD). The presence of these disorders is linked to a more severe course of COVID-19. Given the "epidemic" of obesity worldwide and the importance of obesity in the progression of COVID-19, we investigated the mechanisms through which obesity increases the susceptibility to and severity of COVID-19 to support the selection of more appropriate therapies for individuals with obesity.
Copyright © 2021 Liu, Zhang, Wang and Xia.

Entities:  

Keywords:  COVID-19; obesity; obesity-associated comorbidities; pathophysiology; therapeutic strategies

Mesh:

Year:  2021        PMID: 33776917      PMCID: PMC7992974          DOI: 10.3389/fendo.2021.620566

Source DB:  PubMed          Journal:  Front Endocrinol (Lausanne)        ISSN: 1664-2392            Impact factor:   5.555


  109 in total

Review 1.  Mechanisms involved in the side effects of glucocorticoids.

Authors:  Heike Schäcke; Wolf Dietrich Döcke; Khusru Asadullah
Journal:  Pharmacol Ther       Date:  2002-10       Impact factor: 12.310

2.  Functional and structural changes in the kidney in the early stages of obesity.

Authors:  Jeffrey R Henegar; Steven A Bigler; Lisa K Henegar; Suresh C Tyagi; John E Hall
Journal:  J Am Soc Nephrol       Date:  2001-06       Impact factor: 10.121

Review 3.  Adipokines in inflammation and metabolic disease.

Authors:  Noriyuki Ouchi; Jennifer L Parker; Jesse J Lugus; Kenneth Walsh
Journal:  Nat Rev Immunol       Date:  2011-01-21       Impact factor: 53.106

Review 4.  Leptin and renal fibrosis.

Authors:  Gunter Wolf; Fuad N Ziyadeh
Journal:  Contrib Nephrol       Date:  2006       Impact factor: 1.580

5.  Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions.

Authors:  Toshimasa Yamauchi; Yasunori Nio; Toshiyuki Maki; Masaki Kobayashi; Takeshi Takazawa; Masato Iwabu; Miki Okada-Iwabu; Sachiko Kawamoto; Naoto Kubota; Tetsuya Kubota; Yusuke Ito; Junji Kamon; Atsushi Tsuchida; Katsuyoshi Kumagai; Hideki Kozono; Yusuke Hada; Hitomi Ogata; Kumpei Tokuyama; Masaki Tsunoda; Tomohiro Ide; Kouji Murakami; Motoharu Awazawa; Iseki Takamoto; Philippe Froguel; Kazuo Hara; Kazuyuki Tobe; Ryozo Nagai; Kohjiro Ueki; Takashi Kadowaki
Journal:  Nat Med       Date:  2007-02-01       Impact factor: 53.440

Review 6.  Adipose tissue, inflammation, and cardiovascular disease.

Authors:  Anders H Berg; Philipp E Scherer
Journal:  Circ Res       Date:  2005-05-13       Impact factor: 17.367

7.  Adiponectin suppresses proliferation and superoxide generation and enhances eNOS activity in endothelial cells treated with oxidized LDL.

Authors:  Hiroyuki Motoshima; Xiangdong Wu; Kalyankar Mahadev; Barry J Goldstein
Journal:  Biochem Biophys Res Commun       Date:  2004-03-05       Impact factor: 3.575

8.  ACE2 is expressed in mouse adipocytes and regulated by a high-fat diet.

Authors:  Manisha Gupte; Carine M Boustany-Kari; Kalyani Bharadwaj; Sara Police; Sean Thatcher; Ming C Gong; Victoria L English; Lisa A Cassis
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2008-07-23       Impact factor: 3.619

9.  25-Hydroxyvitamin D Concentrations Are Lower in Patients with Positive PCR for SARS-CoV-2.

Authors:  Antonio D'Avolio; Valeria Avataneo; Alessandra Manca; Jessica Cusato; Amedeo De Nicolò; Renzo Lucchini; Franco Keller; Marco Cantù
Journal:  Nutrients       Date:  2020-05-09       Impact factor: 5.717

10.  Dexamethasone in Hospitalized Patients with Covid-19.

Authors:  Peter Horby; Wei Shen Lim; Jonathan R Emberson; Marion Mafham; Jennifer L Bell; Louise Linsell; Natalie Staplin; Christopher Brightling; Andrew Ustianowski; Einas Elmahi; Benjamin Prudon; Christopher Green; Timothy Felton; David Chadwick; Kanchan Rege; Christopher Fegan; Lucy C Chappell; Saul N Faust; Thomas Jaki; Katie Jeffery; Alan Montgomery; Kathryn Rowan; Edmund Juszczak; J Kenneth Baillie; Richard Haynes; Martin J Landray
Journal:  N Engl J Med       Date:  2020-07-17       Impact factor: 91.245

View more
  4 in total

1.  ‎Factors associated with coronavirus disease 2019 infection severity among a sample of Lebanese adults: Data from a cross-sectional study.

Authors:  Elissar El-Hayek; Georges-Junior Kahwagi; Nour Issy; Christina Tawil; Nabil Younis; Rony Abou-Khalil; Madonna Matar; Souheil Hallit
Journal:  Health Sci Rep       Date:  2022-05-23

2.  Prognostic Role of Subcutaneous and Visceral Adiposity in Hospitalized Octogenarians with COVID-19.

Authors:  Max Scheffler; Laurence Genton; Christophe E Graf; Jorge Remuinan; Gabriel Gold; Dina Zekry; Christine Serratrice; François R Herrmann; Aline Mendes
Journal:  J Clin Med       Date:  2021-11-24       Impact factor: 4.241

3.  Rethinking COVID-19 and Beyond: Prevention, Remedies, and Recovery.

Authors:  Philip B Maffetone; Paul B Laursen
Journal:  Front Public Health       Date:  2022-02-23

Review 4.  Striking the Balance: GLP-1/Glucagon Co-Agonism as a Treatment Strategy for Obesity.

Authors:  David C D Hope; Matthew L Vincent; Tricia M M Tan
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-08       Impact factor: 5.555

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.